← Back to Clinical Trials
Recruiting NCT05329363

NCT05329363 Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05329363
Status Recruiting
Phase
Sponsor University Hospital, Tours
Condition Schizophrenia
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2022-06-17
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
PEPITS ProgrammeUsual care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2022-06-17 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Schizophrenia affects about 0.7% of the population. Poor insight, which is common in this disease, linked to poor drug compliance is leads to rehospitalisation with major impact on quality of life. Indeed, many patients relapse with exacerbation of symptoms. Psychoeducation can improve therapeutic alliance and medication compliance. In this context, an individual psycho-education program (PEPITS) has been developed. PEPITS carried out by nurses during the initial stages of hospitalisation. The hypothesis is that PEPITS program will decrease relapse and improve the compliance and insight and and so the quality of life.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 65 years * Patient with a diagnosed and reported schizophrenic disorder announced : * Schizophrenia * Schizoaffective disorder * Or a diagnosed and reported Delusional Disorder * Express written consent by the participant after receiving information about the study * Be able to communicate verbally * Participant affiliated to a social security scheme Exclusion Criteria: * Pregnant or breastfeeding woman * Patient who does not speak French * Participation in a psycho-education group in the last 2 years * Patient under legal protection or guardianship

Contact & Investigator

Central Contact

Arnaud CHESSE

✉ A.CHESSE@chu-tours.fr

📞 +33(0)2.34.37.89.68

Frequently Asked Questions

Who can join the NCT05329363 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05329363 currently recruiting?

Yes, NCT05329363 is actively recruiting participants. Contact the research team at A.CHESSE@chu-tours.fr for enrollment information.

Where is the NCT05329363 trial being conducted?

This trial is being conducted at Blois, France, Chinon, France, Dreux, France, Fleury-les-Aubrais, France and 7 additional locations.

Who is sponsoring the NCT05329363 clinical trial?

NCT05329363 is sponsored by University Hospital, Tours. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology